Video

Our team behind the scenes at SXSW | Building a Disease Specific Knowledge Base

In part two of our SXSW series, our team shows how we use AI and machine learning to better understand specific diseases - in this case, Glioblastoma (GBM), the most common and aggressive form of brain cancer.

Given the complexity of a savage disease like GBM, a scientist alone could not read up on all the research that has been done to understand it. At BenevolentAI, we have developed a biomedical knowledge base to contextualise all the relevant information and relationships between diseases, genes, drugs and other important research that has already been published.

Our knowledge graph pulls out all the relevant links to ongoing and completed clinical trials, existing compounds that have been tested against the disease, and the underlying biological connections known to be associated with the disease. Together, these biological facts represent all that is known to be true about a disease today.

Our technology platform helps us understand diseases like GBM by sitting on top of this knowledge base and answering two fundamental questions, i) what do we know about the disease today? and ii) where are the gaps in that knowledge base?


Watch our team demonstrate how algorithms can analyse this knowledge and reason across it to provide scientists and researchers with capabilities beyond human insight.

More Posts

You Might Also Like

Events
BenevolentAI at ICML 2020
We are pleased to announce that BenevolentAI is sponsoring the virtual ICML 2020 conference from the 12th - 18th of July. You can find our team on the EXPO workshop and Women in ML stage - we hope to meet you there.
Jul 12, 2020
News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020
Events
New tech brings new hope in our new normal | A Keynote from Joanna Shields at WeAreTechWomen
In this talk, Joanna Shields will demonstrate how human intelligence partnered with technology promises to accelerate new discoveries, new treatments, and new hope for patients.
Jun 26, 2020
Events
Transforming Biopharmaceutical Research with AI at The HESI Annual Meeting 2020.
Our Executive board director, Jackie Hunter, will take to the virtual stage to demonstrate how AI can be used right at the beginning of the R&D process to improve target identification and validation as well as being used to identify key pathways in disease
Jun 9, 2020
Video
How do we get the next 10 years right? | CogX Opening Keynote w/ Joanna Shields
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020